‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌               ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌             
 
 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌   ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 
 
View Full Prescribing Information.
Doptelet
 
 
Help raise and maintain platelet counts with Doptelet (Avatrombopag)
 
DOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1
DOPTELET helps raise and maintain platelet counts1-3:
Patients on DOPTELET were able to increase their platelet count to ≥50x109/L for a median of 12.4 weeks without the need for rescue therapy (P<.0001 vs placebo)1*†
66% of patients treated with DOPTELET achieved a platelet count of ≥50x109/L on Day 81‡
*Study Design: Efficacy was evaluated in a 6-month, multicenter, randomized, double-blind,
placebo-controlled phase 3 study. Patients had previously received one or more prior chronic ITP therapies and had average screening and baseline platelet counts of <30x109/L. Forty-nine patients were randomized (2:1) to receive either DOPTELET (n=32) or placebo (n=17).
The primary efficacy endpoint was the cumulative number of weeks of platelet response, defined as a platelet count ≥50x109/L in the absence of rescue therapy, over 6 months of once-daily treatment in adults with chronic ITP.
A secondary efficacy endpoint was the proportion of patients with a platelet response (platelet count ≥50x109/L) at Day 8.
 
 
 
DOPTELET, an oral thrombopoietin receptor agonist
(TPO-RA)1:
Is taken with food
Has no calcium or other food restrictions
Does not require additional liver-function monitoring
Does not require an office visit for administration
 
DOPTELET is supplied as a 20-mg tablet1:
Recommended Starting Dose 20mg once daily
The recommended starting dose is 20 mg
(1 tablet) once daily
Doses are then titrated up or down as necessary, based on platelet count
Dose adjustments are recommended for patients taking concomitant strong/moderate dual inducers or inhibitors of CYP2C9 and CYP3A4
 
 
 
Dova 1SourceTM provides a full range of healthcare navigation support and financial assistance to help your patients
Dova 1Source
May include access to the DOPTELET Copay Coupon for commercially insured patients. Eligible patients pay $0 for each DOPTELET prescription
To speak to a care coordinator to obtain additional
details and have your questions answered, please call
1-833-DOVA-ONE (1-833-368-2663).
 
 
 
INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions
 
 
DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.
In clinical trials, 7% (9/128) of patients with chronic immune thrombocytopenia treated with DOPTELET developed a thromboembolic event. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).
DOPTELET should not be administered to patients with chronic immune thrombocytopenia in an attempt to normalize platelet counts. Follow the dosing guidelines to achieve target platelet counts.
Contraindications: None
Drug Interactions
Dose adjustments are recommended for patients with chronic immune thrombocytopenia taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.
Adverse Reactions
The most common adverse reactions (≥10%) were: headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.
Please see Full Prescribing Information
https://dova.com/wp-content/uploads/2019/06/doptelet-prescribing-information.pdf
References: 1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc; 2019.
2. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490. 3. Data on file. Dova Pharmaceuticals, Inc.
Visit DopteletHCP.com to learn more
Dova Pharmaceuticals DOPTELET is a registered trademark of AkaRx, Inc.
© 2019 Dova Pharmaceuticals, Inc. All rights reserved.
PM-US-DOP-0199
 
 
click
This email was sent to amy.gonsuron@amerisourcebergen.com because you have an account with or are a valued partner of ION Solutions. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.
AmerisourceBergen - 1300 Morris Dr Chesterbrook PA, 19087
© 2019 ION Solutions. All Rights Reserved.